Medtech Startup CoreTissue BioEngineering to Be the First Japanese Startup at JPOD @ Boston

March 15, 2022 |

1 min read

CoreTissue BioEngineering will expand its footprint and accelerate business development in the US through its support team and select key opinion leaders.

YOKOHAMA, Japan--(BUSINESS WIRE)-- CoreTissue BioEngineering Inc., a medical device company developing an artificial ligament derived from decellularized animal tissue, was accepted into Johnson & Johnson Innovation - JPOD @ Boston.

CoreTissue BioEngineering will expand its footprint and accelerate business development in the US through its support team and select key opinion leaders (KOLs).

About CoreTissue BioEngineering Inc.

Based in Yokohama, Japan, CoreTissue BioEngineering, Inc. is a spinout company from Waseda University in Japan. We feel our team of Harvard-trained biomedical scientist, seasoned senior management in medical device development, and experienced clinical research professional has the right talents to carry this mission to potential success.

Following our success in developing artificial ligament for ACL reconstruction surgery, we plan to further apply our technology platform to the development of medical devices for the broader human musculoskeletal system.
CoreTissue BioEngineering has already validated a proof-of-concept of the product in an ovine large animal study with a prototype developed using these technologies. The company has received strong backing from the Japanese government, the Japan Agency for Medical Research and Development (AMED) for development from early feasibility through pivotal trial.

For more information, visit https://www.coretissue.com/?lang=en